

Title: An Exploration of the Association of Inflammatory Cytokines and the Non-Motor Symptoms of Parkinson's Disease in Patients in DATATOP

Principal Investigator: Matthew Menza, MD, Professor, Psychiatry & Neurology, Robert Wood Johnson Medical School, Piscataway, NJ

This is an exploration of the association of inflammatory cytokines and the non-motor symptoms of Parkinson's disease using stored serum samples and assessments from the DATATOP study. We propose to study both the association between baseline levels of inflammatory cytokines and the cross-sectional severity of non-motor symptoms of PD as well as the longitudinal relationship between these cytokines and the course of these non-motor symptoms. The proposal follows our publication of pilot data from 52 PD depressed patients in which we found significant correlations between peripheral TNF- α and measures of cognition, depression and disability. We believe that this study has the potential to improve our understanding of the pathophysiology of non-motor symptoms as well as to facilitate the development of a biomarker for these symptoms.

Introduction

The physical aspects of Parkinson's disease (PD), such as tremor, rigidity and postural imbalance, are the defining characteristics of the disease and, understandably, they are the focus of most research and clinical care. Nonetheless, PD affects patients' lives in a broader sense than merely by physical impairment. For example, many of the non-motor aspects of PD, such as cognitive impairment, depression and sleep disturbances are common and associated with poor outcomes. These non-motor symptoms are also significant determinants of quality of life (QoL) for these patients and their caregivers.ⁱ At present, both the pathophysiology and clinical treatment of these non-motor symptoms are understudied and poorly understood. Recent advances in cytokine research may present an opportunity for progress in this area. For example, the discovery of multiple functions of cytokines in the central nervous system suggests that cytokines may play a critical role in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease and may affect complex CNS functions such as cognition, sleep and depression.^{ii,iii}

Of particular importance in PD, where widespread mild cognitive impairment is extremely common early in PD and frank dementia is common late in the illness,^{iv} is the association of cytokines with cognitive deterioration. Recent cross-sectional and prospective studies of Alzheimer's and vascular dementia have suggested that particular cytokines are associated with cognitive impairment in these patients,^{v,vi} raising the possibility that the study of inflammatory cytokines in PD may improve our understanding of the associated cognitive impairment.

The cytokines most commonly associated with the "inflammatory" response are IL1 β , IL-6, and TNF- α , which individually can alter neuroendocrine activity^{vii}, increase neurotransmitter release^{viii}, induce regional activation of immediate early genes in the brain, and modify basic behaviors, such as food ingestion, locomotion and sleep,^{ix} as well as learning and memory and anhedonia.^x Furthermore, systemic inflammatory mechanisms generate neurochemical, endocrine and behavioral alterations similar to that observed in response to psychogenic stressors.^{xi,xii}

There is evidence linking elevated levels of TNF- α directly to PD. In animals, there are increases in cytokines, including TNF- α in the substantia nigra after injection of MPTP or 6-OHDA and multiple studies indicate that TNF is highly toxic to dopaminergic neurons.^{xiii} Furthermore, TNF- α levels are elevated in the cerebrospinal fluid and postmortem brains of PD patients^{xiv} and nonsteroidal anti-inflammatory drug use has been associated with a lower risk of developing PD in large US cohort studies.^{xv} These studies suggest, despite variability, that cytokines, and TNF- α in particular, are related to the clinical expression of the symptoms of PD.^{xvi}

We recently completed an NIH-funded, randomized, controlled trial of nortriptyline, controlled release paroxetine, and placebo in patients with PD and depression.^{xvii,xviii} Because of the potential involvement of inflammatory cytokines in the symptoms of PD, we developed a supplement to this study to evaluate the association between inflammatory cytokines and the non-motor symptoms of PD. We found that TNF- α (but not IL-1 β , IL-6, IL-10 or cortisol) was significantly correlated with measures of cognition, depression and disability. In regression analyses, accounting for all variables, TNF- α was consistently significant in explaining variance in cognition, depression and disability.^{xix}

We are interested in extending these findings and this study will explore the relationship between TNF- α and other cytokines (IL-1 β , IL-6, IL-10, IFN γ) and measures of non-motor symptoms in 200 patients in the DATATOP study. We hypothesize that there will be significant associations between TNF- α and measures of cognition, depression and disability. We further hypothesize that baseline TNF- α will be a predictor of the longitudinal course of these symptoms.

Potential impact: We believe that this study has high potential impact as it may help to establish cytokines as important biomarkers for the non-motor symptoms of PD. In addition, it may help to jumpstart a systematic approach to cytokine research in non-motor aspects PD – an area of high public health significance.

ⁱ. McKinlay A, Grace RC, Dalrymple-Alford JC, Anderson T, Fink J, Roger D. A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. *Parkinsonism Relat Disord.* 2008;14(1):37-42. Epub 2007 Jul 12.

ⁱⁱ. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to Sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008;9:46-56.

ⁱⁱⁱ. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. *Neuroscience and Biobehavioral Reviews* 2009;33:355–366.

^{iv}. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. *Arch Neurol* 2003;60:387–92.

^v. Mrazek RE, Griffin WST. Potential Inflammatory biomarkers in Alzheimer's disease *Journal of Alzheimer's Disease* 2005;8:369–375.

^{vi}. Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. *Neurology* 2005;64:1371-1377.

^{vii}. Szelenyi, J., 2001. Cytokines and the central nervous system. *Brain Res. Bull.* 2001;54 (4):329–338.

^{viii}. Pickering, M., Cumiskey, D., et al.,. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. *Exp. Physiol.* 2005;90 (5), 663–670.

^{ix}. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor-and cytokine-induced alterations of neuroplasticity. *Neuroscience* 2005;135:659-678.

^x. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al.

Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. *Mol Psychiatry* 2008 ;13:717-728.

^{xi}. Anisman H, Merali Z, Poulter MO, Hayley S: Cytokines as a precipitant of depressive illness: animal and human studies. *Curr Pharm Des* 2005;11:963-972.

^{xii}. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to Sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008;9:46-56.

^{xiii}. Carvey PM, Chen EY, Lipton JW, Tong CW, Chang QA, Ling ZD: Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. *J Neural Transm* 2005, 112:601-612.

^{xiv}. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC: Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. *Neurosci Lett* 1994, 172:151-154.

^{xv}. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. *Ann Neurol*. 2005 Dec;58(6):963-7.

^{xvi}. Nagatsu T and Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. *Cellular and Molecular Neurobiology* 2006;26(4-6):781-802.

^{xvii}. Menza M, Dobkin R, Marin H, Mark M, Gara M, Buyske S, Bienfait K, Allison A. A Controlled Trial of Antidepressants in Patients with Parkinson's Disease and Depression. *Neurology* 2009;72:886-892.

^{xviii}. Menza M, Dobkin R, Marin H, Mark M, Gara M, Buyske S, Bienfait K, Allison A. The impact of treatment of depression on quality of life, cognition and relapse in patients with Parkinson's disease. *Movement Disorders* 2009;24;9:1325-1332.

^{xix}. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnecov A. The Role of Inflammatory Cytokines in Cognition and other Non-Motor Symptoms of Parkinson's Disease. In press at *Psychosomatics*.